Fig. 2From: The “rights” of precision drug development for Alzheimer’s diseaseSpectrum of AD and the corresponding cognitive and biomarker state of trial participants (A, amyloid abnormalities; T, tau abnormalities; N, neurodegeneration)Back to article page